Notable biotech firm Sanofi is experiencing a whirlwind of activity. The company is under investigation by a South African watchdog, along with Novo Nordisk, for possible anti-competitive actions in the insulin market. Amidst this, Sanofi has returned a midstage ILT2 asset to Biond Biologics following a risky $125M investment, while also facing scrutiny over implementing an unauthorised 340B rebate proposal.
In a potential setback, Johnson & Johnson halted a Phase III trial on Sanofi’s E. Coli vaccine due to insufficient effectiveness, leading to a $250M charge on study failure for Sanofi. However, not all is grim for the biotech company. Enveda Biosciences received support to advance AI-Driven drug discovery to clinical trials, gathering a significant $150M in a Series C financing round that included Sanofi. The company has also made strides with their bowel disease bets, providing stiff competition for rivals Merck and Roche. Additionally, Sanofi got its first FDA approval for a NovoLog Biosimilar, simultaneously challenging Novo.
Sanofi has also multiple new updates and prospects on its pipeline such as a radioligand pioneer activity and an in vivo program. Commitment to environmentally sustainable practices is also evident as Sanofi supports healthcare system decarbonization and improving lives through lower emissions. Finally, robust earnings from Dupixent and new RSV Vaccine continues to fuel its financial performance, with a key spotlight on executive committee with CFO Francois Roger at helm.
Sanofi News Analytics from Wed, 22 May 2024 07:00:00 GMT to Sat, 08 Mar 2025 18:00:00 GMT - Rating 0 - Innovation 5 - Information 6 - Rumor 2
